Tenascin-c enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Paron, Igor ^a,b   Berchtold, Sonja ^a,b   Vörös, Julia ^a   Shamarla, Madhavi ^a   Erkan, Mert ^c   Höfler, Heinz ^a,b   Esposito, Irene ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; INTEGRIN; PAXILLIN; PROTEIN KINASE B; TENASCIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL ASSAY; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CELL SPREADING; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; METASTASIS; PANCREAS CANCER; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR PROMOTION; CELL MOTION; CELL SURVIVAL; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVATION; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; ENZYME ACTIVATION; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRINS; PANCREATIC NEOPLASMS; PAXILLIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TENASCIN;

EID: 79959659734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021684     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Baxter NN, Whitson BA, Tuttle TM, (2007) Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 14: 1320-1326.
3. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M, (2009) Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35: 335-339.
4. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, et al. (2008) Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 68: 2085-2093.
5. Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, et al. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907-921.
6. Omary MB, Lugea A, Lowe AW, Pandol SJ, (2007) The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 117: 50-59.
7. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
8. Pas J, Wyszko E, Rolle K, Rychlewski L, Nowak S, et al. (2006) Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol 38: 1594-1602.
9. Jones FS, Jones PL, (2000) The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 218: 235-259.
10. Fischer D, Tucker RP, Chiquet-Ehrismann R, Adams JC, (1997) Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Mol Biol Cell 8: 2055-2075.
11. Midwood KS, Orend G, (2009) The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal.
12. Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, et al. (1991) Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 22: 636-643.
13. Erickson HP, Bourdon MA, (1989) Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 5: 71-92.
14. Chiquet-Ehrismann R, Chiquet M, (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200: 488-499.
15. Orend G, (2005) Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 37: 1066-1083.
16. Juuti A, Nordling S, Louhimo J, Lundin J, Haglund C, (2004) Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol 57: 1151-1155.
17. Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, et al. (2006) Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 208: 673-685.
18. Drucker BJ, Marincola FM, Siao DY, Donlon TA, Bangs CD, et al. (1988) A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. In Vitro Cell Dev Biol 24: 1179-1187.
19. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, et al. (2003) A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452.
20. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M, (1988) Tenascin interferes with fibronectin action. Cell 53: 383-390.
21. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, et al. (2005) Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 25: 489-495.
22. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G, (2001) Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61: 8586-8594.
23. Jang JH, Chung CP, (2005) Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett 229: 101-105.
24. End P, Panayotou G, Entwistle A, Waterfield MD, Chiquet M, (1992) Tenascin: a modulator of cell growth. Eur J Biochem 209: 1041-1051.
25. Crossin KL, (1991) Cytotactin binding: inhibition of stimulated proliferation and intracellular alkalinization in fibroblasts. Proc Natl Acad Sci U S A 88: 11403-11407.
26. Erickson HP, (1993) Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 5: 869-876.
27. Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula VL, (2003) Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology 42: 280-291.
28. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, et al. (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98: 2430-2439.
29. Zamecnik J, Chanova M, Tichy M, Kodet R, (2004) Distribution of the extracellular matrix glycoproteins in ependymomas--an immunohistochemical study with follow-up analysis. Neoplasma 51: 214-222.
30. Giese A, Loo MA, Norman SA, Treasurywala S, Berens ME, (1996) Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins. J Cell Sci 109 (Pt 8): 2161-2168.
31. Sriramarao P, Mendler M, Bourdon MA, (1993) Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Sci 105 (Pt 4): 1001-1012.
32. Giancotti FG, Ruoslahti E, (1990) Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60: 849-859.
33. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, et al. (2001) Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439: 798-802.
34. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, et al. (2009) Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11: R24.
35. Esposito I, Kayed H, Keleg S, Giese T, Sage EH, et al. (2007) Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 9: 8-17.
36. Geback T, Schulz MM, Koumoutsakos P, Detmar M, (2009) TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 46: 265-274.